Brainstorm Cell

BCLI NASDAQ
3.990
-0.070
-1.72%
Closed 16:00 07/19 EDT
Open
4.130
Prev Close
4.060
High
4.130
Low
3.880
Volume
90.61K
Avg Vol (3M)
57.84K
52 Week High
4.500
52 Week Low
2.920
% Turnover
0.42%
Market Cap
86.60M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Brainstorm Cell BCLI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
MORE >

Recently

Name
Price
%Change